Another clinical trial (NCT02824133) evaluating the efficacy of AZD4547 (FGFR1–3 inhibitor) in glioma patients with FGFR3–TACC3 fusion is under recruitment [78]. The gene discussed is FGFR3; the disease is central nervous system cancer.